In a report released today, Matt Miksic from Barclays maintained a Buy rating on Globus Medical (GMED – Research Report), with a price target ...

In a report released today, David Saxon from Needham maintained a Hold rating on Globus Medical (GMED – Research Report). The company’s shares ...

Globus Medical GMED continues to gain from surging demand for its Musculoskeletal Solutions products. However, a challenging macroeconomic scenario continues to plague Globus Medical. The stock ...

The company currently has its sales operations distributed across 51 counties worldwide. GMED is a Zacks Rank #3 (Hold) stock, with a Growth Style Score of A and VGM Score of A. Earnings are ...

Globus Medical, Inc.’s GMED growth in the third quarter can be attributed to the robust prospect in the musculoskeletal space. The company’s merger with NuVasive is expected to generate ...

The most recent guidance for Globus Medical (GMED) was reported on January 8, 2025 for the full year 2025. The company provided earnings per share guidance in the range of $3.40 to $3.50 ...

The company currently has its sales operations distributed across 51 counties worldwide. GMED is a #3 (Hold) on the Zacks Rank, with a VGM Score of B. Additionally, the company could be a top pick ...